Krystal Biotech is strategically positioned in the biotech sector with its unique focus on developing genetic medicines for rare diseases, offering a promising investment opportunity. Krystal ...

Transcription and translation are processes a cell uses to make all proteins the body needs to function from information stored in the sequence of bases in DNA. The four bases (C, A, T/U, and G in the ...

Genetic engineering, also known as genetic modification, is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks ...

The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout ...

AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets identified by the biotech’s RNA platform designed to help create treatments for ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Shares of UniQure, the Netherlands-based gene therapy ...

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...

Most biotechs don't have a diversified business model. They typically develop hardware, diagnostic tests, or drugs, as well as some of the associated platform technologies. But a few competitors, like ...

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business. 23andMe's strategy will take longer to pay off, but it could ...